论文部分内容阅读
目的：了解卵巢癌腹腔化疗前后血清可溶性白细胞介素－２受体（ＳＩＬ－２Ｒ）的变化。方法：采用双抗体夹心酶联免疫吸附试验（ＥＬＩＳＡ法）检测４１例卵巢癌患者在腹腔化疗前后血清ＳＩＬ－２Ｒ水平，并与正常对照组比较。结果：卵巢癌患者在腹腔化疗前血清ＳＩＬ－２Ｒ水平显著高于正常对照组（Ｐ＜０．００１），水平升高与病灶大小呈正相关；治疗后患者血清ＳＩＬ－２Ｒ水平比治疗前明显下降（Ｐ＜０．００１），但仍显著高于对照组（Ｐ＜０．０５），与病情变化密切相关；治疗有效的患者血清ＳＩＬ－２Ｒ水平明显低于无效患者的水平（Ｐ＜０．０５）。结论：卵巢癌患者血清ＳＩＬ－２Ｒ的变化与癌肿的大小及消长呈正相关，在腹腔化疗前后检测患者的血清ＳＩＬ－２Ｒ水平，有助于估计病情、疗效及预后。
Objective: To investigate the changes of serum soluble interleukin-2 receptor (SIL-2R) in patients with ovarian cancer before and after intraperitoneal chemotherapy. Methods: Serum levels of SIL-2R in 41 patients with ovarian cancer before and after intraperitoneal chemotherapy were measured by double antibody sandwich enzyme-linked immunosorbent assay (ELISA) and compared with the normal control group. Results: The serum level of SIL-2R in patients with ovarian cancer before chemotherapy was significantly higher than that in normal controls (P <0.001), and the level of SIL-2R was positively correlated with the size of the lesion. The level of serum SIL-2R in patients with ovarian cancer was significantly lower than that before treatment (P <0.001), but it was still significantly higher than that of the control group (P <0.05), which was closely related to the changes of the disease. The level of serum SIL-2R in patients with effective treatment was significantly lower than that in patients with ineffectiveness (P <0.001). 05). CONCLUSIONS: The change of serum SIL-2R in ovarian cancer patients is positively correlated with the size and growth of cancer. The level of serum SIL-2R in patients with ovarian cancer before and after intraperitoneal chemotherapy is helpful to evaluate the condition, curative effect and prognosis.